Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.
Our work is reader-supported. Sign up to our free or paid plans here.
Here, in the first of a series of Op-Eds that focus on alternative psychedelics access models, Healing Advocacy Fund’s Executive Director, Taylor West, shares her views on how state psychedelic programs are shaping up and what we might learn from them.
Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Antagonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus Pharma, Lists on Nasdaq • Compass Details PTSD Trial Design, Reaffirms TRD Launch Readiness ‘By End of Year’ • Emory Registers Trial of MDMA-Assisted Massed Exposure Therapy in Active Duty Troops • Filings Provide a Look at Psychedelics Nonprofits’ Finances • and more…
In the third video of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look at some broader open questions and potential futures in the psychedelics field via a narrated presentation.
Psychedelic Alpha looks back on 2025, highlighting the ten stories that defined a pivotal year for psychedelic drug development, policy, and access, as well as key interviews and reflections from across the field. All Pα+ stories featured in this Top 10 are available to read, for free, throughout January 2026.
In the second of a three-part series, Psychedelic Alpha’s Josh Hardman looks ahead to 2026 via a narrated presentation. In this video, Hardman considers potential FDA approvals, Phase 3 readouts, alternative pathways to access, and more.
In the first of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look back at 2025 via a narrated presentation. In this hour-long video, Hardman reviews developments across psychedelic drug development, policy, industry, and access programs in the year gone by.
Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.
The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.
It’s exclusively available to our Pα+ subscribers, with new content added regularly.
Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.
Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.
The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.
Archived versions of our Psychedelic News Feed.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing January 05, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 15, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 8, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing December 01, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 24, 2025.
Your one-stop digest for the latest coverage of psychedelics business, policy, research and beyond, for the week commencing November 17, 2025.
Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond
Insights and interviews delivered to your inbox. No spam, just valuable information.
